Breakthrough in Cancer Gene Therapy: Targeted Delivery of RNAs Shows Promise

Strategic Insights -

Researchers at Yale University have made significant progress in the development of a novel cancer gene therapy. According to a recent study published in Science Translational Medicine, a tumor-targeting, cell-penetrating monoclonal antibody, TMAB3, has been found to form stable, noncovalent antibody/RNA complexes that mediate highly specific and functional delivery of RNAs into tumors. The results showed robust antitumor efficacy of systemically administered TMAB3/RNA complexes in mouse models of pancreatic cancer, medulloblastoma, and melanoma.

Key Takeaways:

  • The study used a tumor-targeting, cell-penetrating monoclonal antibody, TMAB3, which formed stable, noncovalent antibody/RNA complexes to deliver RNAs into tumors.
  • The TMAB3/RNA complexes showed robust antitumor efficacy in mouse models of pancreatic cancer, medulloblastoma, and melanoma.
  • Treatment with TMAB3/3p-hpRNA complexes tripled animal survival, decreased tumor growth, and specifically targeted malignant cells in a KPC syngeneic, orthotopic pancreatic cancer model.
  • Single-cell RNA sequencing and flow cytometry demonstrated a potent antitumoral immune response characterized by RIG-I activation and increased infiltration and activity of cytotoxic T cells.
  • The study established that TMAB3/RNA complexes can deliver RNA payloads specifically to hard-to-treat tumor cells to achieve antitumor efficacy.
  • This research provides an antibody-based platform to advance the study of RNA therapies for the treatment of patients with cancer.
  • Funders for this research include the National Institutes of Health (NIH), Damon Runyon Cancer Research Foundation, American Association for Cancer Research Career Development Award in Pancreatic Cancer Research, Pew Cancer Research Scholars Award, and others.
  • The therapeutic potential of this approach was demonstrated in multiple mouse models of cancer, paving the way for future clinical trials.

Statistics:

  • The study reported a 1500-fold difference in RNA delivery into tumor cells versus nonmalignant cells within the tumor mass.
  • Single-cell RNA sequencing and flow cytometry demonstrated a robust antitumoral immune response characterized by RIG-I activation and increased infiltration and activity of cytotoxic T cells.
  • Treatment with TMAB3/3p-hpRNA complexes tripled animal survival in a KPC syngeneic, orthotopic pancreatic cancer model.

Sources:

  • Systemic Administration of an Rna Binding and Cell-penetrating Antibody Targets Therapeutic Rna To Multiple Mouse Models of Cancer. Science Translational Medicine, 2025;17(807).
  • Yale University, School of Medicine, Dept. of Therapeutic Radiology, New Haven, CT 06520, United States.
  • National Institutes of Health (NIH), Damon Runyon Cancer Research Foundation, American Association for Cancer Research Career Development Award in Pancreatic Cancer Research, Pew Cancer Research Scholars Award, and others.